Weekly roundup: Science, strategy, and shifting policy

The winds they are a-changin’, with the tail-end of Hurricane Erin bringing what feels like an abrupt end to summer here in northern Europe. And what will the new season bring to the world of biotech and pharma? Only time will tell. Optimum’s clients are certainly gearing up though – and we can all expect […]

Hot topic: From mRNA to mRNO – What impact will US funding cuts have on the technology?

The US administration’s decision to stop federal funding worth $500 million for research into mRNA-based vaccines has not gone down well with the scientific community. Researchers argue the premise for the cuts – that in the words of US Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., mRNA vaccines “fail to […]

Weekly roundup: From summer’s end to science’s cutting edge

It’s still holiday season – but in the UK that’s almost over, with the end of summer traditionally marked by the long ‘bank holiday’ weekend (Monday 25th August is a public holiday in England and Wales), after which thoughts return to work. Expect September to begin with a bang, as everyone rushes to tell the […]

Hot topic: What, where, when? Mapping out the top life science conferences to attend in the next six months

Will we see you there? The Optimum team has taken a moment to map out the top life science conferences to attend in the next six months. As an official partner to many of the top events, Optimum is pleased to be able to provide discount codes to our network – do reach out for […]

Weekly roundup: This week’s best biopharma beach read

This week hasn’t been the busiest (mid-August rarely is), but Eli Lilly dropped a minor bombshell on Thursday by saying it would hike the UK prices of its popular weight-loss drug Mounjaro by up to 170% (that’s nearly threefold in old money). But the increases – which came after the US administration reiterated calls for […]